Skip to main content
Erschienen in: Diabetologia 11/2013

01.11.2013 | Commentary

Tipping the inflammatory balance: inflammasome activation distinguishes metabolically unhealthy from healthy obesity

verfasst von: Rinke Stienstra, Norbert Stefan

Erschienen in: Diabetologia | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Expansion of adipose tissue mass, predominantly in the visceral depot, strongly associates with the development of metabolic complications that are often observed in obesity. In addition, in obesity, an increased prevalence of nonalcoholic fatty liver disease and reduced cardiorespiratory fitness are observed. However, not all obese individuals develop metabolic abnormalities. To better understand the molecular mechanisms that predispose obese humans to the development of metabolic diseases, comparing the metabolically healthy obese (MHO) vs an unhealthy obese phenotype (MUO) may be of great value. A new study by Esser et al (DOI:10.​1007/​s00125-013-3023-9) now provides important evidence that the MHO phenotype is associated with a lower activation of the NOD-like receptor family pyrin domain containing-3 (NLPR3) inflammasome in macrophages of visceral adipose tissue and a more favourable inflammatory profile as compared with the MUO phenotype. This finding could promote novel studies in humans to decipher stimuli and mechanisms leading to increased inflammasome activity, not only in adipose tissue, but also in other organs that are involved in the regulation of metabolism.
Literatur
1.
Zurück zum Zitat Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRef Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRef
2.
Zurück zum Zitat Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMed Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMed
3.
Zurück zum Zitat Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMed Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMed
4.
Zurück zum Zitat Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–184PubMedCrossRef Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175–184PubMedCrossRef
5.
Zurück zum Zitat Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363–374PubMedCrossRef Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363–374PubMedCrossRef
6.
Zurück zum Zitat Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107PubMedCrossRef Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98–107PubMedCrossRef
7.
Zurück zum Zitat Cipolletta D, Feuerer M, Li A et al (2012) PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486:549–553PubMed Cipolletta D, Feuerer M, Li A et al (2012) PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486:549–553PubMed
8.
Zurück zum Zitat DeFuria J, Belkina AC, Jagannathan-Bogdan M et al (2013) B cells promote inflammation in obesity and type 2 diabetes through regulation of T cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A 110:5133–5138PubMedCrossRef DeFuria J, Belkina AC, Jagannathan-Bogdan M et al (2013) B cells promote inflammation in obesity and type 2 diabetes through regulation of T cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A 110:5133–5138PubMedCrossRef
9.
10.
Zurück zum Zitat Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG (2012) The inflammasome puts obesity in the danger zone. Cell Metab 15:10–18PubMedCrossRef Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG (2012) The inflammasome puts obesity in the danger zone. Cell Metab 15:10–18PubMedCrossRef
11.
Zurück zum Zitat Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411PubMedCrossRef Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13:397–411PubMedCrossRef
12.
Zurück zum Zitat Seok J, Warren HS, Cuenca AG et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512PubMedCrossRef Seok J, Warren HS, Cuenca AG et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512PubMedCrossRef
13.
Zurück zum Zitat Esser N, L’homme L, De Roover A et al (2013) Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia doi:10.1007/s00125-013-3023-9 Esser N, L’homme L, De Roover A et al (2013) Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia doi:10.​1007/​s00125-013-3023-9
14.
Zurück zum Zitat Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285PubMedCrossRef Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285PubMedCrossRef
15.
Zurück zum Zitat Reynolds CM, McGillicuddy FC, Harford KA, Finucane OM, Mills KH, Roche HM (2012) Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res 56:1212–1222PubMedCrossRef Reynolds CM, McGillicuddy FC, Harford KA, Finucane OM, Mills KH, Roche HM (2012) Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res 56:1212–1222PubMedCrossRef
16.
Zurück zum Zitat Stefan N, Häring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19:394–395PubMedCrossRef Stefan N, Häring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19:394–395PubMedCrossRef
17.
Zurück zum Zitat Klöting N, Fasshauer M, Dietrich A et al (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299:E506–E515PubMedCrossRef Klöting N, Fasshauer M, Dietrich A et al (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299:E506–E515PubMedCrossRef
18.
Zurück zum Zitat Stefan N, Häring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9:144–152PubMedCrossRef Stefan N, Häring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9:144–152PubMedCrossRef
19.
Zurück zum Zitat Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616PubMedCrossRef Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616PubMedCrossRef
20.
Zurück zum Zitat Stefan N, Häring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60:2011–2017PubMedCrossRef Stefan N, Häring HU (2011) The metabolically benign and malignant fatty liver. Diabetes 60:2011–2017PubMedCrossRef
21.
Zurück zum Zitat Lehmann R, Franken H, Dammeier S et al (2013) Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 36:2331–2338PubMedCrossRef Lehmann R, Franken H, Dammeier S et al (2013) Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver. Diabetes Care 36:2331–2338PubMedCrossRef
22.
Zurück zum Zitat Hasegawa H, Lei J, Matsumoto T, Onishi S, Suemori K, Yasukawa M (2011) Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun 25:526–531CrossRef Hasegawa H, Lei J, Matsumoto T, Onishi S, Suemori K, Yasukawa M (2011) Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun 25:526–531CrossRef
23.
Zurück zum Zitat Lamkanfi M, Kanneganti TD, van Damme P et al (2008) Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics 7:2350–2363PubMedCrossRef Lamkanfi M, Kanneganti TD, van Damme P et al (2008) Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics 7:2350–2363PubMedCrossRef
24.
Zurück zum Zitat Chalkiadaki A, Guarente L (2012) High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab 16:180–188PubMedCrossRef Chalkiadaki A, Guarente L (2012) High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab 16:180–188PubMedCrossRef
Metadaten
Titel
Tipping the inflammatory balance: inflammasome activation distinguishes metabolically unhealthy from healthy obesity
verfasst von
Rinke Stienstra
Norbert Stefan
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 11/2013
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-3040-8

Weitere Artikel der Ausgabe 11/2013

Diabetologia 11/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.